Tag: biomedical
-
Novartis, NGO Partner on Generic Antibiotics
Drug maker Novartis and a not-for-profit organization delivering antibiotics for low- and middle-income countries are collaborating on production of generic antibiotics for children.
-
Antibody Combination Shown to Suppress HIV
Results from a small-scale clinical trial show a combination of antibodies can suppress the HIV virus for many weeks after stopping antiretroviral therapy.
-
$29.5M Funding Raised for Sinus Drug Delivery Company
A company developing a drug delivery technology to treat chronic sinus conditions is raising $29.5 million in its second venture financing round.
-
Genome Centers Named for Precision Medicine Program
Three medical research centers in the U.S. will begin analyzing the DNA in specimen samples from participants in a large-scale precision medicine initiative conducted by National Institutes of Health.
-
Umbilical Cord Grafts Shown to Heal Foot Ulcers
Results from a clinical trial show skin grafts made from dehydrated human umbilical cord tissue heal more diabetic foot ulcers than alginate dressings, a common treatment for the condition.
-
Synthetic Antibody Neutralizing Gluten in Development
An academic-business team is developing a synthetic antibody to prevent gluten found in some grains from affecting the intestines of people with celiac disease, an intolerance of gluten.
-
Algorithms Advance Assistive Control for Spinal Cord Injury
A system to control movements of an assistive sleeve is shown in lab tests to enable a person with no use of his arms and legs due to spinal cord injury to accurately grasp and release objects.
-
Liquid Biopsy for Solid Tumors Now Available
A test that inspects a patient’s blood sample for characteristic indicators of solid-tumor cancer, and can be part of a comprehensive precision analytics program, is now on the market.
-
Infographic — “Wearables” Means Worn on Wrist
The term “wearables” in most cases means a device worn on the wrist.
-
Spin-Off Company Developing New Antibiotics
A start-up enterprise in the U.K. is commercializing research from a university lab that discovered a new class of antibiotics promising to treat drug-resistant bacterial infections.